Clinical trials: Time Management
Relapsing Forms of Multiple Sclerosis
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
- Trial name
- TIMIOS (NCT04676555)
- Testing
- Ocrelizumab, Ofatumumab
- Where
- 2 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
The primary objective of the trial is to determine the effect of BI 17444Cl on the lung function over a 24-hour period, when it is inhaled using the Respimat inhaler in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00846768
- Testing
- BI 1744 CL
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
AKI - Acute Kidney Injury, Cardiac Surgery
Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device.
- Conditions
- AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability
- Trial name
- NCT07022314
- Testing
- FIZE kUO®
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- FIZE Medical ltd
Endometriosis
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis, describe dose effect relationship and duration of symptom relief
- Trial name
- NCT00244452
- Testing
- Cetrorelix
- Where
- 57 sites in Australia, Belgium and 6 more
- Sponsor
- Solvay Pharmaceuticals
Lymphedema
Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema
The objective of the study is to assess the effect of a new Armsleeve, worn during the night during maintenance phase of upper limb lymphoedema treatment in combination with Day-time usual lymphology hosiery.
- Trial name
- MARILYN (NCT02253186)
- Testing
- Auto-Adjustable MOBIDERM Armsleeve
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Thuasne
Healthy Subjects
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)
The primary purpose of this study is to investigate the effect of Aprocitentan (ACT-132577) at steady state on the pharmacokinetics of single-dose rosuvastatin in healthy male subjects
- Trial name
- NCT03245229
- Testing
- Aprocitentan, Rosuvastatin
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
- Trial name
- NCT07569926
- Testing
- fluciclovine (18F)
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- Blue Earth Diagnostics
Healthy
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)
- Trial name
- NCT03832452
- Testing
- Lucerastat (Treatment A), Moxifloxacin, Lucerastat (Treatment B)
- Where
- Netherlands
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy Subjects
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin
A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin
- Trial name
- NCT03339752
- Testing
- Rosuvastatin, ACT-541468
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pupil Constriction
Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia
Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pupil size.
- Trial name
- NCT06783686
- Testing
- NV701, Pilocarpine 1.25% Eye drop
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novus Vision LLC
Heart Failure
AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure
To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) in a Phase 3…
- Trial name
- FLOURISH (NCT03360448)
- Testing
- Ad5.hAC6
- Sponsor
- Renova Therapeutics
Healthy Subjects
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects
- Trial name
- NCT03657446
- Testing
- Clazosentan, Moxifloxacin
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hepatitis B, Chronic
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
- Trial name
- NCT03866187
- Testing
- ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation
- Where
- 43 sites in Belgium, France and 7 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Physician Education
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated…
- Trial name
- SMART (NCT02287025)
- Testing
- Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bayer
Osteoarthritis of the Knee
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
- Trial name
- NCT02003365
- Testing
- FX006 10 mg, FX006 40 mg, TCA IR 40 mg
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Healthy
Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL
The objective ot the present study is to obtain information about safety, tolerability and preliminary pharmacokinetics of BIII 890 CL after single intravenous administration of increasing doses in healthy male volunteers.
- Trial name
- NCT02268136
- Testing
- BIII 890 CL
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Neutropenia, Breast Cancer
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when administered at varying intervals following Docetaxel and Cyclophosphamide…
- Trial name
- NCT04187898
- Testing
- Eflapegrastim, Docetaxel, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 59 people
- Sponsor
- Spectrum Pharmaceuticals, Inc